Research paper
DNA rearrangements in Japanese facioscapulohumeral muscular dystrophy patients: clinical correlations

https://doi.org/10.1016/0960-8966(94)00055-EGet rights and content

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscular disorder in which the disease locus has been mapped to chromosome 4q35-qter. In most patients, the DNA rearrangements associated with FSHD have been found in the EcoRI fragment detected by the p13E-11 probe, and deletions of the 3.2 kb repeat units within the fragment are thought to cause the disease. To examine FSHD-associated DNA rearrangements in the Japanese population, we performed Southern blot analysis of the genomic DNA, using the p13E-11 and pFR-1 probes, in 158 Japanese individuals, including 38 FSHD patients from 19 families. We found that all but one (a possible affected recombinant) of the Japanese FSHD patients (97.4%) had specific smaller (<28 kb) EcoRl fragments which cosegregated with the disease; this included four patients who had severe inflammatory changes in the muscle and eight patients with de novo DNA rearrangements. We found no FSHD patient who had a fragment larger than 28 kb. By contrast, only two of 35 Japanese controls (5.7%) had EcoRI fragments smaller than 28 kb. Our patients showed anticipation, i.e. decreased size of the EcoRI fragment in parallel with earlier onset of the disease (r=0.531, P=0.003, with younger age at onset in children (17.8±7.0) than their affected parents (31.5±14.8) (P=0.019). However, since each family had a specific small EcoRI fragment associated with the disease, the differing clinical severity within a family cannot be explained by the size of the fragment alone. We found two severely affected patients (new mutations) who had the shortest EcoRI fragment ever reported (10 kb) that contained no more than one 3.2 kb repeat unit. None of the patients with neurogenic scapuloperoneal muscular atrophy had smaller EcoRI fragments detected by the probes. We conclude that the p13E-11 and pFR-1 probes are tightly linked markers of FSHD and can detect most DNA rearrangements associated with the disease in the Japanese population.

References (30)

  • P.W. Lunt et al.

    Estimation of age dependent penetrance in facioscapulohumeral muscular dystrophy by minimizing ascertainment bias

    J. Med Genet

    (1989)
  • R. Tawil et al.

    Extreme variability of expression in monozygotic twins with FSH muscular dystrophy

    Neurology

    (1993)
  • G.M. Fenichel et al.

    Neurogenic atrophy simulating facioscapulohumeral dystrophy: a dominant form

    Arch Neurol

    (1967)
  • C. Wijmenga

    Facioscapulohumeral muscular dystrophy: from genetic mapping towards gene cloning

  • C. Wijmenga et al.

    Mapping of facioscapulohumeral muscular dystrophy gene to chromosome 4q35-qter by multipoint linkage analysis and in situ hybridization

    Genomics

    (1191)
  • Cited by (39)

    • Genetic and epigenetic contributors to FSHD

      2015, Current Opinion in Genetics and Development
      Citation Excerpt :

      Moreover, approximately 1–2% of healthy control individuals carries a D4Z4 repeat array of 8–10 units on a 4qA allele, putting them at risk of developing FSHD [17,18]. Early studies already suggested a rough and inverse relationship between D4Z4 repeat size and disease severity in FSHD1, with individuals carrying 1–3 units typically representing the most severe end of the disease spectrum [48–51]. Recent studies have, however, started to uncover some aspects of the molecular basis of this marked clinical variability in disease onset and progression.

    • The FSHD2 gene SMCHD1 Is a modifier of disease severity in families affected by FSHD1

      2013, American Journal of Human Genetics
      Citation Excerpt :

      Previous studies were only partially successful in explaining the variation in clinical severity in individuals with FSHD1. In addition to the inverse correlation with the residual repeat size,9,11,12,37 CpG methylation and histone modification studies of D4Z4 have likewise uncovered only rough correlations between residual methylation levels and clinical severity, with the most severely affected individuals with the smallest repeat sizes showing the largest reduction in repressive chromatin modifications.38,39 To identify modifiers of disease severity, of particular interest are those families with FSHD1 carrying upper-sized D4Z4 repeat arrays of 8–10 units, as shown by the fact that carriers of these alleles are more likely to have a partial or less severe form of FSHD or to be asymptomatic.40–42

    • FSHD-like patients without 4q35 deletion

      2004, Journal of the Neurological Sciences
    View all citing articles on Scopus
    View full text